Bristol Myers Squibb stock gains with solid dividend and strong one-year run

Published on 09/13/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock closed at USD 63.52 on September 11, 2026, and is up 17.8 percent since the start of the year. The company’s market capitalization stands at about USD 129.99 billion in September 2026 with a forward annual dividend of USD 2.52 per share.

Impressionistische Aquarellmalerei der New Yorker Skyline bei Dämmerung, Wolkenkratzer-Silhouetten in weichen Blau- und Bernsteinwaschen mit Lichtreflexionen auf nassen Straßen — Bristol-Myers Squibb US0897961004 Aquarell New Yorker Skyline beleuchtet durch Abenddämmerung mit goldenen Straßenreflexionen, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US0897961004) is trading firmly in the mid-60-dollar range, with a recent closing price of USD 63.52 on September 11, 2026 on the New York Stock Exchange, while the shares have risen about 17.8 percent since the beginning of the year according to MarketBeat.

Dividend yield and market capitalization attract income investors

Income-oriented investors currently see Bristol Myers Squibb as a yield play, with a forward annual dividend of USD 2.52 per share, paid in quarterly installments of USD 0.63, and a dividend yield of about 3.94 percent based on a share price of USD 63.62 as of September 11, 2026, according to Yahoo Finance.

The company’s stock market valuation underscores its role as a large-cap pharmaceutical name: Bristol Myers Squibb’s market capitalization was reported at USD 129.99 billion as of September 12, 2026, placing it around the 176th most valuable company globally, according to data compiled by CompaniesMarketCap.

For context, the same overview points to a one-year share price change of 37.75 percent and a daily move of negative 0.17 percent for a recent session in September 2026, illustrating both the longer-term recovery in the stock and the short-term volatility that remains a feature of large pharmaceutical equities, according to CompaniesMarketCap.

Share performance and return comparisons over one year

The recent performance numbers give investors a clearer picture of how Bristol Myers Squibb stock has behaved over different horizons. From the beginning of 2026, when the shares traded at USD 53.93, the stock has appreciated to about USD 63.52, an increase of roughly 17.8 percent over that year-to-date period according to MarketBeat.

Meanwhile, the longer one-year development highlighted in the market capitalisation data shows a gain of about 37.75 percent over the past twelve months, suggesting that the bulk of the share price recovery has occurred gradually over that period rather than in a short-lived spike, according to CompaniesMarketCap.

The dividend-focused analysis from Yahoo Finance additionally illustrates what this yield profile means in practical terms: at a dividend yield of about 3.94 percent and a share price of USD 63.62, an investor seeking USD 10,000 in annual dividend income from Bristol Myers Squibb would need roughly 3,968 shares, corresponding to about USD 252,000 invested at current levels, according to Yahoo Finance.

Clinical pipeline context and sector positioning

While the latest search results do not carry a full quarterly report, Bristol Myers Squibb remains deeply involved in oncology and immunology research, with recent commentary pointing to positive topline data from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T-cell therapy for multiple myeloma, according to a scientific note cited by OncoDaily.

For shareholders, such clinical milestones form part of the medium-term fundamental backdrop, complementing the share price and dividend metrics described above. A solid market capitalization near USD 130 billion and a dividend yield close to 4 percent provide a foundation, while clinical progress in key programs can influence expectations for future revenue and earnings beyond the current reporting periods, according to the same commentary via OncoDaily.

Stock price level and investor perspective

At a recent closing price of USD 63.52 on the New York Stock Exchange as of September 11, 2026, Bristol Myers Squibb stock is trading materially above its level at the beginning of the year, while offering a forward annual dividend of USD 2.52 per share and a yield of about 3.94 percent at a share price of USD 63.62, giving investors a combination of capital appreciation over roughly one year and regular income, based on data from MarketBeat and Yahoo Finance.